Objective -To examine the survival of patients with breast cancer diagnosed in different centres and by different methods in the United Kingdom trial of early detection of breast cancer, in order to investigate the contribution of different factors to the previously observed reductions in breast cancer mortality. Setting -A non-randomised trial of the early detection of breast cancer, in which women aged 45-64 in two districts were offered annual screening for seven years, women in a further two districts were offered education about breast self examination (BSE), and those in four districts formed a comparison group. Methods -Patients with breast cancer are classified according to the type of centre, method of detection, and attendance for BSE education. Univariate and multivariate survival analyses are carried out, including tumour size, dissemination status, and use of adjuvant treatment as additional variables. Results -In the univariate analysis, patients with breast cancer who are nonattenders for screening have a significantly worse prognosis than those in the comparison centres. Patients whose cancer is detected by mammography have the best survival rate. The inclusion of size and dissemination status in the multivariate analysis explains only about one third of the improved prognosis in these cases. There is a significant difference between prognosis in the two BSE centres. Conclusions -The use of prognostic factors as recorded in this trial to predict breast cancer mortality may be inadequate.
The UK trial of early detection of breast cancer is a non-randomised trial that began in 1979 and was designed to compare mortality from breast cancer in two districts offering women annual screening for seven years, two districts in which women were offered education in breast self examination (BSE), and four control districts in which no intervention took place.
After 10 years' follow up a 20% reduction in breast cancer mortality was observed in the two screening districts combined compared with the control districts, after adjustment for mortality before the trial.' There was no reduction in the two BSE districts combined compared with the control districts, but a significant difference between the two, with Huddersfield showing a mortality reduction similar to that observed in the screening districts. 2 An earlier randomised controlled trial of mammography screening in Sweden found a 30% reduction in breast cancer mortality after 11 years.' This study concluded that the improved survival of patients with breast cancer in the intervention group, excluding those detected at the first screening round and those in women who did not accept the screening invitation could be very largely accounted for by differences in size, grade, and nodal status at diagnosis. The authors imply that in future trials the effect of screening on mortality might be predicted by surrogate end points -namely, size, grade, and nodal status of breast cancers in screened women diagnosed after the first screening round, compared with breast cancers in a control group who had not been invited for screening.
The present paper examines the survival of patients with breast cancer diagnosed in the different trial centres and by different methods, and attempts to investigate the factors contributing to reduced mortality.
Method
The methodology of the trial has been described in detail elsewhere." The two screening centres, Guildford and Edinburgh, each offered women aged 45-64 screening by clinical examination every year, with mammography in years 1, 3, 5, and 7, though inevitably not all women followed this schedule exactly. The two BSE districts, Huddersfield and Nottingham, invited women in the same age group to attend an education session on BSE, with access to open clinics without referral by a general practitioner for those suspecting an abnormality. No intervention occurred in the four control
Attenders (n=410)
Non-attenders (n=433) in SSE centres districts (Oxford, Avon, Stoke, and Dundee). Data on all breast cancers diagnosed -during the seven year period of the trial fieldwork were obtained from local searches of clinical and pathology laboratory records and through flagging at the NHS central registries. Thus some cases will have been included which were treated outside the trial districts. Information on type of treatment, including use of adjuvant radiotherapy, chemotherapy and/or hormone therapy, was also collected locally. For all breast cancers the size and nodal status categories were based on histological findings wherever these were available, but supplemented by clinical findings in other cases. Histological grade was recorded routinely in only two of the eight centres, and is not reported here.
The cases of breast cancer included in the present analysis occurred during the seven year period of the fieldwork of the trial, in the initial cohort of women aged 45-64 at entry. All deaths up to December 1990 were included, and follow up was censored at that date. Breast cancers diagnosed in the screening centres were classified as diagnosed by screening (either at a first or subsequent mammographic screening or a clinical only screening), as interval cases, or as cancers in non-responders to the screening invitation (never screened). Cases detected by screening were classified according to the modality performed rather than that due at a particular screening round. An interval cancer was defined as one occurring after a negative screening examination, and diagnosed either completely outside the screening programme, or after a woman had self referred or had been referred by her doctor back to the screening clinic. Cases diagnosed at any time after a negative screen were classed as interval cases, including those where subsequent screening invitations were not accepted. In the BSE centres, cases were classified according to whether or not the woman attended for BSE education.
The size of invasive cancers was analysed in categories: 1-10 mm, 11-20 mm, 21-50 mm, and >50 mm, with unknown size treated as a separate category. Dissemination status was classified as negative, positive lymph nodes only, or distant metastases present, again with unknown as a separate category, but with presence of distant metastases overriding unknown lymph node status. With such a large number of cancers in eight different health districts many different surgical and histopathology teams were involved and there was considerable variability in their policies on axillary node sampling or dissection, and on the number of nodes examined. Cases were classified according to whether any adjuvant treatment (hormone or chemotherapy) was used initially.
Survival analysis by the Cox proportional hazards method was carried out with the statistical package EGRET. 5 In the survival analysis in situ cases were excluded, and deaths from causes other than breast cancer were treated as censoring events. .0 20 .... Results Figure 1 shows the percentage of cancers in Detected by screening the different size categories for the three types of centre, and for cancers diagnosed by different means in the screening centres. The shift towards small sizes in the screening centres (which may result from an increase in detection of small lesions without necessarily any decrease in larger lesions) was concentrated in the mammographically detected cancers, with a lesser shift in the clinically detected. There was a greater proportion oflarge tumours in the non-attenders than in the comparison centre patients. Figure 2 shows the percentage of cancers in the different dissemination status categories in each centre and according to means of diagnosis. Some caution is necessary in the interpretation because of the variable proportion of cancers of unknown nodal status in different centres. Again the shift towards node negative cases was greatest in the mammographically detected lesions, while the non-attenders had a high proportion of cases with distant metastases. Table 1 shows the results of the Cox proportional hazard survival analysis, with method of detection, nodal status, and size included individually as regression variables. Dissemination status and size had the expected effect on survival. The prognosis for the nonattenders was significantly worse than for the comparison centre patients. Patients with mammographicaly detected lesions had the best survival, with patients with clinically detected lesions and interval cases having significantly better survival than the comparison centre patients. Table 2 shows the results of a multivariate survival analysis, with method of detection in the screening centres, individual BSE centres, size, and dissemination status fitted simultaneously. When size and dissemination status were included the hazard ratio in the nonattenders in the screening centres no longer ... increasing from 0·23 to 0·51 with the inclusion of these factors. Comparisons of survival between cases detected with and without screening are always subject to lead time bias, length bias, and selection bias. Lead time bias is due to the spurious increase in patient survival as a result of the time by which diagnosis is advanced by screening; length bias is due to the tendency of screening to pick up slower growing cases, which may in turn have a better prognosis. differed significantly from that in the comparison centre patients. Likewise, the hazard ratio in the interval cancer cases and patients with clinically detected lesions were no longer significantly lower.
The inclusion of size and dissemination status increased the hazard ratio for cancers detected by mammography from 0·25 to 0·39 for first round detected cancers, and from 0·23 to 0'51 for cancers detected at other rounds. For both groups, however, the prognosis remained significantly better than for comparison centre patients.
Inclusion of age at entry (in five year age groups from 45 to 64) or use of adjuvant treatment made little difference to the results of the multivariate analysis.
The effect of attendance for education in BSE remained significant in the multivariate analysis; there was no significant interaction between individual BSE centres. Figures 3-5 show the survival of patients in the two screening centres, the two BSE centres, and the four comparison centres respectively. There was little difference in the survival in the two screening centres (fig 3) , but there was a significant difference in survival between the two BSE centres (fig 4) . The difference between the comparison centres ( fig 5) was non-significant, and was reduced when size and nodal status were included in the analysis.
Discussion
The results suggest that only about one third of the improved prognosis in cases detected by mammographic screening is explained by changes in prognostic factors, the hazard ratio This makes a direct estimate of the effect of screening from such analyses impossible.
In some screening trials, however, there is a clear correlation between a shift in prognostic factors and outcome of screening.
The multivariate analysis shows that both the poor prognosis in cases among nonattenders for screening and the better prognosis among interval cases are largely explained by differences in stage at presentation, the nonattenders tending to present at later stages, and the interval cases to be early stage relative to the comparison centre patients.
The slight benefit among cases detected at clinical only screening also appears to be due to a shift to earlier stage at diagnosis. The more favourable prognosis among cases detected at a first mammographic screening round, after adjustment for size and dissemination status, will be largely due to length bias; a first screening will tend to pick up a higher proportion of slow growing tumours than later screening rounds. There may also be variations of prognostic factors within categories, with "node positive" cancers detected by screening, for example, having on average fewer positive nodes than the "node positive" controls." The fact that the prognosis of cases detected at subsequent mammographic screening remains significantly better, even after the same adjustment for size and dissemination status, differs from the conclusions of the Swedish trial,' in which a similar multivariate analysis found a non-significant difference between cancers detected at subsequent screening and those in the control group (hazard ratio 0'69, 95% confidence interval 0'47 to 1'02). Possible reasons why size and dissemination status do not explain the better survival of the United Kingdom trial cases detected at subsequent mammographic screening Include the fact that it was not possible to adjust simultaneously for grade. This might also suggest that length bias was still present among cancers detected at subsequent mammographic screening. However, Duffy et at infer from the Swedish data that grade may increase with tumour progression 7 ; in this case the more favourable prognosis will reflect the benefit due to detection at an earlier grade. In addition, dissemination status was unknown for a relatively large proportion of cases, and the adjustment for use of adjuvant therapy might not have fully accounted for therapeutically important differences in treatment. The most obvious reason for the lesser effect of screening on breast cancer mortality in this trial compared with the Swedish two counties? study is the difference in compliance (67% and 89% respectively). However, even when selection of patients with a poor prognosis into the non-attenders is taken into account, the benefit observed in the attenders in this trial remains lower than in the same group in Sweden.
Although breast cancer incidence in the control population in the two studies is similar, the corresponding mortality from breast cancer is higher in the UK, 8 which suggests that the stage at presentation here tends to be more advanced. The percentage in the "unknown" categories in tables 1 and 2 make this difficult to confirm or refute, but there is a suggestion that the percentage of comparison centre patients with tumours >50 mm or with distant metastases, or both, is greater than in the Swedish control group.
It should be noted that, in centres which examine the histology of all axillary nodes, rather than merely a sample for apparently early stage cancers, survival of cases classified as node negative will automatically appear better than in centres which do not examine all nodes as the latter will include an unknown number ofnode positive cases with poor prognosis in the node negative group." Normal practice varied between the centres. For instance, information on nodal status was available in 86% of cases in Edinburgh, compared with 48% in Guildford. In Huddersfield and Nottingham nodal examination was carried out on a similar proportion of cases, but in Nottingham only 1-3 nodes were usually examined. Nevertheless, it is of interest that there was no significant difference between Huddersfield and Nottingham in the proportion of cancers over 20 mm in diameter (52'6% and 48·8% respectively), despite the significantly better prognosis for the Huddersfield patients.
If, without screening, diagnosis tends to be at a later stage in the United Kingdom, and if screening is equally sensitive in both countries, we should expect to observe a higher cancer detection rate at the first screening round in the United Kingdom than in Sweden. The fact that the detection of invasive cases actually was slightly lower in the United Kingdom implies that, although the overall sensitivity in the United Kingdom does not seem to be lower than in Sweden," a greater proportion of late stage tumours (for which one would expect the sensitivity to be greater) may be masking a poorer sensitivity for the detection of small tumours.
A higher risk of patient death in cases detected by screening in the United Kingdom is also indicated by the fact that, before adjustment for size and nodal status, the hazard for cancers detected by screening relative to the controls is similar in the two studies," whereas owing to the poorer survival of the comparison centre patients than those in the Swedish control group, one might expect a greater relative benefit in the United Kingdom. This higher patient death in the United Kingdom from cancers detected by screening might reflect a difference in the quality of mammography, which is thought to have been inferior to that in Sweden at the beginning of the United Kingdom trial, but to have improved over time.
The better survival among those attending for BSE education than in non-attenders may be due to residual selection bias even after adjustment for size and nodal status. This effect is apparent in both BSE centres.
The reasons for the significant difference between the two BSE centres is unclear, and has been explored in detail elsewhere." Nottingham had a higher initial uptake of education about BSE than did Huddersfield (53'1% v 31,4%), but the reverse was true for attendance at open access clinics (2'2% and 4·9% respectively). It is not possible to infer from available data what proportion of women were practising BSE in each district, but as their stage distributions were similar it seems unlikely that more widespread practice of BSE made a large contribution to the better prognosis in Huddersfield. Adjuvant radiotherapy, endocrine treatment, and chemotherapy were each used much more often in treatment of breast cancers in Huddersfield than Nottingham. Adjuvant endocrine treatment and chemotherapy are now known to improve survival in early breast cancer,II although an estimation of the extent to which equal use of these treatments for early breast cancer might have reduced the difference between these two centres suggested that it made only a marginal difference." Hence the reasons for the better prognosis for women with breast cancer in Huddersfield remain largely obscure.
The differences highlighted between the Swedish and United Kingdom findings stress the need for collection of standardised information on prognostic factors for the continuing evaluation of the United Kingdom screening programme. These results also indicate the need for caution in the use of prog-Moss, Ellman, Coleman, Chamberlain nostic factors as "interim end points" in the evaluation of breast screening, because clearly those based on size and dissemination status alone do not adequately explain the findings of the United Kingdom trial.
